How to buy Anebulo Pharmaceuticals stock | $7.2

Anebulo Pharmaceuticals Inc is a biotechnology business based in the US. Anebulo Pharmaceuticals shares (ANEB) are listed on the NASDAQ and all prices are listed in US Dollars. Anebulo Pharmaceuticals employs 2 staff and has a market cap (total outstanding shares value) of 0.00.

Anebulo Pharmaceuticals stock price (NASDAQ: ANEB)

Use our graph to track the performance of ANEB stocks over time.

Anebulo Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-10-17.

Latest market close	$7.20
52-week range	$6.31 - $8.79
50-day moving average	$6.88
200-day moving average	$7.14
Wall St. target price	$15.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.83

Buy Anebulo Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Anebulo Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Anebulo Pharmaceuticals price performance over time

Historical closes compared with the close of $7.2 from 2021-10-18

1 week (2021-10-12)	6.92%
1 month (2021-09-20)	6.51%
3 months (2021-07-20)	1.41%
6 months (2021-04-16)	N/A

1 year (2020-10-16)	N/A
2 years (2019-10-16)	N/A
3 years (2018-10-16)	N/A
5 years (2016-10-16)	N/A

Anebulo Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-18.3%
Return on equity TTM	-249.85%
Profit margin	0%
Book value	$0.92
Market capitalisation	$167.6 million

TTM: trailing 12 months

Shorting Anebulo Pharmaceuticals shares

There are currently 5,601 Anebulo Pharmaceuticals shares held short by investors – that's known as Anebulo Pharmaceuticals's "short interest". This figure is 34.7% down from 8,571 last month.

There are a few different ways that this level of interest in shorting Anebulo Pharmaceuticals shares can be evaluated.

Anebulo Pharmaceuticals's "short interest ratio" (SIR)

Anebulo Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Anebulo Pharmaceuticals shares currently shorted divided by the average quantity of Anebulo Pharmaceuticals shares traded daily (recently around 4746.6101694915). Anebulo Pharmaceuticals's SIR currently stands at 1.18. In other words for every 100,000 Anebulo Pharmaceuticals shares traded daily on the market, roughly 1180 shares are currently held short.

To gain some more context, you can compare Anebulo Pharmaceuticals's short interest ratio against those of similar companies.

• Pfizer (PFE.US): 1.98
• AstraZeneca (AZN.US): 1.14
• AbbVie (ABBV.US): 1.43

However Anebulo Pharmaceuticals's short interest can also be evaluated against the total number of Anebulo Pharmaceuticals shares, or, against the total number of tradable Anebulo Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Anebulo Pharmaceuticals's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Anebulo Pharmaceuticals shares in existence, roughly 0 shares are currently held short) or 0.0024% of the tradable shares (for every 100,000 tradable Anebulo Pharmaceuticals shares, roughly 2 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Anebulo Pharmaceuticals.

Find out more about how you can short Anebulo Pharmaceuticals stock.

Anebulo Pharmaceuticals share dividends

We're not expecting Anebulo Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

• Pfizer (PFE.US) (3.7% forward annual dividend yield)
• AstraZeneca (AZN.US) (4.63% forward annual dividend yield)
• AbbVie (ABBV.US) (4.66% forward annual dividend yield)

Anebulo Pharmaceuticals overview

Anebulo Pharmaceuticals, Inc. , a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas. .

Frequently asked questions

What percentage of Anebulo Pharmaceuticals is owned by insiders or institutions?
Currently 75.551% of Anebulo Pharmaceuticals shares are held by insiders and 18.008% by institutions. How many people work for Anebulo Pharmaceuticals?
Latest data suggests 2 work at Anebulo Pharmaceuticals. When does the fiscal year end for Anebulo Pharmaceuticals?
Anebulo Pharmaceuticals's fiscal year ends in December. Where is Anebulo Pharmaceuticals based?
Anebulo Pharmaceuticals's address is: 1415 Ranch Road 620 South, Lakeway, TX, United States, 78734 What is Anebulo Pharmaceuticals's ISIN number?
Anebulo Pharmaceuticals's international securities identification number is: US0345691036